Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2010

View Archived Issues

PAF-R is potential target to treat psoriasis

RAAM-DHF trial finds eplerenone may benefit patients with diastolic heart failure

Lundbeck and Argenta disclose promising preclinical data on MCH1 receptor antagonists

Enoxaparin yields superior net clinical benefit to UFH in subjects undergoing PCI for STEMI

Almirall describes pre-candidate agents for multiple sclerosis

Consistent stability data for Adventrx's ANX-530 to support NDA submission

Abbott responds to FDA advisory committee vote regarding sibutramine

DHEAS levels in plasma identified as putative biomarker for fibromyalgia

Domain Therapeutics describes new adenosine A2A and A3 receptor antagonists

CytoGenix presents preclinical data on DNA vaccine CYDBA-507 for avian flu

Atox Bio doses first participant in phase I AB-103 study

Phase II data reported on STX-209 in autism spectrum disorders

Resverlogix modifies phase II ASSURE trial of RVX-208

SK Holdings presents new inhibitors of MAO-B

Derma Sciences to complete enrollment in phase II trial of DSC-127

TransPharma completes phase Ia ViaDerm-GLP1 agonist trial

Banyu Pharma identifies new inhibitors of wee1-like protein kinase

GSK and Genmab to refocus ofatumumab development program

Immune Targeting Systems begins phase I trial of FP-01

Orexo grants NewBridge rights to market Abstral in Middle East and Africa

Eisai describes new inhibitors of beta-amyloid peptide production

Lonza to manufacture five monoclonal antibodies for GSK under new agreement

Enrollment of first cohort complete in phase I trial of PV-10 for liver cancer

Phase I trial data reported for Pluristem's PLX-PAD in critical limb ischemia

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...